|
Logo placeholder
|
| Location |
Boston, MA, USA |
| Type |
Academic Medical Center |
| Affiliation |
Harvard Medical School |
| Founded |
1994 (Brigham and Women's) |
| Website |
brighamandwomens.org |
| Focus Areas |
Alzheimer's Disease, Parkinson's Disease, ALS, FTD, Neuroinflammation |
¶ Brigham and Women's Hospital
Brigham And Women'S Hospital is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Brigham and Women's Hospital (BWH) is a world-renowned academic medical center affiliated with Harvard Medical School in Boston, Massachusetts. Founded in 1994 through the merger of two Harvard-affiliated hospitals, BWH has become one of the leading research and clinical care institutions in the United States. The hospital's neuroscience research programs cover a broad spectrum of neurodegenerative diseases, from basic science discoveries to clinical trials.
BWH was formed by the merger of two prestigious Harvard-affiliated hospitals:
- Brigham Hospital (founded 1914) - Named after Dr. Henry Jacob Bigelow and Peter Bent Brigham
- Women's Hospital (founded 1887) - One of the first teaching hospitals for women in the United States
The combined institution has become a leader in medical research, with particular strength in neuroscience and neurodegeneration.
BWH maintains comprehensive Alzheimer's research programs:
- Amyloid and Tau Biology: Investigating APP processing, A-beta aggregation, and tau pathology mechanisms
- Neuroimaging: Advanced PET and MRI studies for early detection and progression tracking
- Biomarker Development: CSF and blood biomarkers for diagnosis and clinical trials
- Clinical Trials: Leading Phase I-III trials for disease-modifying therapies
- Prevention Studies: Identifying modifiable risk factors and preventive interventions
¶ Parkinson's Disease and Movement Disorders
Research programs include:
- Alpha-synuclein biology and Lewy body pathology
- LRRK2 and GBA genetic studies
- Deep brain stimulation research
- Clinical trials for novel therapeutics
¶ ALS and Motor Neuron Disease
BWH researchers investigate:
- SOD1, C9orf72, FUS, and TARDBP mechanisms
- TDP-43 proteinopathy
- Novel therapeutic targets and biomarkers
¶ Neuroinflammation and Microglia
The Center for Neurological Diseases at BWH focuses on:
- Microglial activation in neurodegeneration
- TREM2 and other microglial receptors
- Neuroimmune interactions
Research programs investigate:
- Tau and TDP-43 pathology
- Genetic forms of FTD (GRN, MAPT, C9orf72)
- Clinical phenotype characterization
The Center for Neurological Diseases at BWH coordinates research across multiple neurodegenerative conditions, bringing together basic scientists and clinicians to accelerate translation.
The Ann Romney Center for Neurologic Diseases is a major research initiative focused on developing treatments for Alzheimer's, Parkinson's, ALS, MS, and brain tumors.
BWH is home to leading researchers in neurodegeneration:
- Dr. Dennis Selkoe - Pioneer in amyloid biology and Alzheimer's disease research, co-discoverer of A-beta [1]
- Dr. Michael Ehlers - Former Chief Scientific Officer, neuroscientist
- Dr. Reisa Sperling - Director of the Center for Alzheimer's Research and Treatment [2]
- Dr. John Hardy - Geneticist known for APP and tau research [4]
BWH operates specialty clinics for:
- Memory Disorders Clinic
- Movement Disorders Center
- ALS Clinic
- Frontotemporal Dementia Program
BWH offers extensive training in neurodegeneration research:
- Postdoctoral fellowships in neuroscience
- Clinical research fellowships
- Medical student research opportunities
- Resident and fellowship training in neurology
BWH maintains research collaborations with:
- Harvard Medical School departments
- Massachusetts General Hospital
- University of Cambridge
- Karolinska Institutet
- Other leading institutions worldwide
The study of Brigham And Women'S Hospital has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 8(6):595-608. PMID:27025652
- Sperling RA, et al. (2014). The impact of amyloid-beta on brain function in Alzheimer's disease. Neuron. 81(2):342-352. PMID:24462099
- Holtzman DM, et al. (2011). Alzheimer's disease: the challenge of the second century. Science Translational Medicine. 3(77):77sr1. PMID:21471435
- Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297(5580):353-356. PMID:12130773
- Bateman RJ, et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New England Journal of Medicine. 367(9):795-804. PMID:22784036
- Jack CR, et al. (2013). Tracking pathophysiological processes in Alzheimer's disease. Lancet Neurology. 12(2):207-216. PMID:23332364
- Querfurth HW, LaFerla FM. (2010). Alzheimer's disease. New England Journal of Medicine. 362(4):329-344. PMID:20107219
- Palop JJ, Mucke L. (2010). Synaptic injury and gamma oscillations in Alzheimer's disease. Neuron. 66(5):687-701. PMID:20547126